Related Experiment Video
Updated: Mar 19, 2026
Genotypic Inference of HIV-1 Tropism Using Population-based Sequencing of V3
Published on: December 27, 2010
Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment
Javier Ampuero1, K Rajender Reddy1, Manuel Romero-Gomez1
1Javier Ampuero, Manuel Romero-Gomez, Inter-Centre Unit of Digestive Diseases and CIBERehd, Virgen Macarena, Virgen del Rocío University Hospitals, University of Sevilla, 41018 Sevilla, Spain.
Aim:
To address the therapeutic efficacy of various treatment regimens in genotype 3 selecting randomized clinical trials and prospective National Cohort Studies.
Methods:
(1) PEG-INF-based therapy including sofosbuvir (SOF) + RBV for 12 wk vs SOF + RBV 24 wk; (2) SOF + RBV therapy 12 wk/16 wk vs 24 wk; and (3) the role of RBV in SOF + daclatasvir (DCV) and SOF + ledipasvir (LDV) combinations. This meta-analysis provides robust information with the intention of addressing treatment strategy for hepatitis C virus genotype 3.
Results:
A combination treatment including SOF + RBV + PEG-IFN for 12 wk notes better SVR than with only SOF + RBV for 12 wk, although its association with more frequent adverse effects may be a limiting factor. Longer duration therapy with SOF + RBV (24 wk) has achieved higher SVR rates than shorter durations (12 or 16 wk). SOF + LDV are not an ideal treatment for genotype 3.
Conclusion:
Lastly, SOF + DCV combination is probably the best oral therapy option and the addition of RBV does not appear to be needed to increase SVR rates substantially.
Related Concept Videos
01:25Hepatitis
01:10Retrovirus Life Cycles
02:56Treatment Resistent Cancers